Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial. Shares in the Anglo-US biotech rose sharply ...

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...

"The potential of BlueRock and AskBio's clinical candidates to treat Parkinsons disease could be immense," said Wolfram Carius, head of cell and gene therapy at Bayer. "For the first time ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

In trials at University College London Hospitals (UCLH), an ASO is being used to target the mutated gene that results in the ...

Currently there are seven drug candidates for Parkinson’s disease in Phase III trials ... in our efforts to advance our cell and gene therapy pipeline and deliver on our ambition to be an ...

AskBio begins patient randomizing in phase II gene therapy trial for Parkinson’s disease: Berlin, Germany Wednesday, January 15, 2025, 14:00 Hrs [IST] AskBio Inc. (AskBio), a ge ...

In two new papers, researchers from The Jackson Laboratory (JAX) report the successful use of two approaches—gene therapy and ...

AskBio Inc. (AskBio), a gene therapy company wholly owned and ... in its Phase II clinical trial in patients with Parkinson’s disease (PD). “The randomization of the first participants in ...

14, 2025 — There may be a link between hearing impairment and an increased risk of developing Parkinson's according ... for a given disease against five databases that provide gene-disease ...

Additional details on the meeting can be found at the WORLD Symposium website. About Spur Therapeutics Spur Therapeutics is a clinical-stage biotechnology company focused on developing life-changing ...